Gilmore O’Neill, M.B., M.M.Sc., serves as the President and Chief Executive Officer at Editas Medicine Inc., a leading genome editing company. Dr. O’Neill has a distinguished career in the biopharmaceutical industry, marked by his extensive experience in drug development and strategic leadership. Prior to joining Editas Medicine, he held the position of Chief Medical Officer at Akebia Therapeutics, where he played a pivotal role in advancing the company’s clinical programs and regulatory strategies. His earlier career includes significant roles at Millennium Pharmaceuticals and Amgen, where he contributed to the development of several successful therapeutics. Dr. O’Neill’s academic background is equally impressive, with a medical degree from the Royal College of Surgeons in Ireland and a Master of Medical Science in Clinical Investigation from the Harvard-MIT Division of Health Sciences and Technology. His expertise in clinical development and translational medicine has been instrumental in guiding Editas Medicine’s mission to translate genome editing technology into a novel class of human therapeutics. Under his leadership, Editas Medicine has made significant strides in developing CRISPR-based therapies for a range of genetic disorders, including inherited retinal diseases and blood disorders. As President and CEO, Gilmore O’Neill is responsible for steering the strategic direction of Editas Medicine, overseeing the company’s research and development efforts, and fostering key partnerships. His visionary approach and commitment to innovation have positioned Editas Medicine at the forefront of the genome editing field. Dr. O’Neill’s leadership has not only driven the company’s growth but also reinforced its dedication to improving patient lives through cutting-edge genetic medicine.